SCYNEXIS Inc
Suletud
4.77 3.47
Ülevaade
Aktsiahinna muutus
24h
Min
4.59
Max
4.95
Sissetulek | -34M -21M |
|---|---|
Aktsiakasum | -0.418 |
Kasumimarginaal | 65.741 |
Töötajad | 18 |
EBITDA | -29M -17M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +473.77% upside |
Turukapital | 53M |
|---|---|
Eelmine avamishind | 1.3 |
Eelmine sulgemishind | 4.77 |
SCYNEXIS Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
SCYNEXIS Inc Prognoos
Hinnasiht
By TipRanks
473.77% tõus
12 kuu keskmine prognoos
Keskmine 28 USD 473.77%
Kõrge 32 USD
Madal 24 USD
Põhineb 2 Wall Streeti analüütiku instrumendi SCYNEXIS Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest SCYNEXIS Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
